ENTA – Enanta Pharmaceuticals Inc
Float Short %
14.27
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
-0.17
EPS Last/This Y
1.76
EPS This/Next Y
0.51
Price
8.28
Target Price
18.57
Analyst Recom
1.71
Performance Q
11.74
Relative Volume
1.35
Beta
0.82
Ticker: ENTA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | ENTA | 8.01 | 0.05 | 0.00 | 2623 |
| 2025-08-18 | ENTA | 8.19 | 0.03 | 0.00 | 2440 |
| 2025-08-19 | ENTA | 8.44 | 0.03 | 0.00 | 2456 |
| 2025-08-20 | ENTA | 8.78 | 0.03 | 0.00 | 2454 |
| 2025-08-21 | ENTA | 8.59 | 0.03 | 0.00 | 2457 |
| 2025-08-22 | ENTA | 8.82 | 0.03 | 0.00 | 2457 |
| 2025-08-25 | ENTA | 8.65 | 0.03 | 0.00 | 2457 |
| 2025-08-26 | ENTA | 8.66 | 0.03 | 0.00 | 2457 |
| 2025-08-27 | ENTA | 8.52 | 0.03 | 0.00 | 2457 |
| 2025-08-28 | ENTA | 8.68 | 0.03 | 0.00 | 2457 |
| 2025-08-29 | ENTA | 8.39 | 0.03 | 0.69 | 2465 |
| 2025-09-02 | ENTA | 9.01 | 0.05 | 100.00 | 2551 |
| 2025-09-03 | ENTA | 8.8 | 0.11 | 0.00 | 2701 |
| 2025-09-04 | ENTA | 8.88 | 0.11 | 0.00 | 2706 |
| 2025-09-05 | ENTA | 8.86 | 0.11 | 0.06 | 2719 |
| 2025-09-08 | ENTA | 8.96 | 0.10 | 0.00 | 2773 |
| 2025-09-09 | ENTA | 9.05 | 0.10 | 0.00 | 2776 |
| 2025-09-10 | ENTA | 8.3 | 0.11 | 0.84 | 2779 |
| 2025-09-11 | ENTA | 8.65 | 0.13 | 0.00 | 2939 |
| 2025-09-12 | ENTA | 8.28 | 0.12 | 0.00 | 3208 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | ENTA | 8.01 | 17.3 | - | -4.01 |
| 2025-08-18 | ENTA | 8.19 | 34.9 | - | -4.01 |
| 2025-08-19 | ENTA | 8.39 | 34.9 | - | -4.01 |
| 2025-08-20 | ENTA | 8.78 | 34.9 | - | -4.01 |
| 2025-08-21 | ENTA | 8.55 | 34.9 | - | -4.01 |
| 2025-08-22 | ENTA | 8.82 | 23.0 | - | -4.01 |
| 2025-08-25 | ENTA | 8.65 | 23.0 | - | -4.01 |
| 2025-08-26 | ENTA | 8.65 | 23.0 | - | -4.01 |
| 2025-08-28 | ENTA | 8.69 | 23.0 | - | -4.01 |
| 2025-08-29 | ENTA | 8.40 | 23.0 | - | -4.01 |
| 2025-09-02 | ENTA | 9.02 | 23.0 | - | -3.69 |
| 2025-09-03 | ENTA | 8.82 | 23.0 | - | -3.69 |
| 2025-09-04 | ENTA | 8.90 | 23.0 | - | -3.69 |
| 2025-09-05 | ENTA | 8.85 | 23.0 | - | -3.72 |
| 2025-09-08 | ENTA | 8.91 | 25.4 | - | -3.72 |
| 2025-09-09 | ENTA | 9.00 | 25.4 | - | -3.72 |
| 2025-09-10 | ENTA | 8.31 | 25.4 | - | -3.72 |
| 2025-09-11 | ENTA | 8.66 | 25.4 | - | -3.72 |
| 2025-09-12 | ENTA | 8.28 | 25.4 | - | -3.72 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | ENTA | 0.00 | -8.75 | 13.75 |
| 2025-08-18 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-19 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-20 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-21 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-22 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-25 | ENTA | 0.00 | -1.98 | 13.75 |
| 2025-08-26 | ENTA | 0.00 | -1.98 | 13.75 |
| 2025-08-27 | ENTA | 0.00 | -1.98 | 14.53 |
| 2025-08-28 | ENTA | 0.00 | -1.98 | 14.53 |
| 2025-08-29 | ENTA | 0.00 | -1.98 | 14.53 |
| 2025-09-02 | ENTA | 0.00 | -1.90 | 14.53 |
| 2025-09-03 | ENTA | 0.00 | -1.90 | 14.53 |
| 2025-09-04 | ENTA | 0.00 | -1.90 | 14.53 |
| 2025-09-05 | ENTA | 0.00 | -1.90 | 14.53 |
| 2025-09-08 | ENTA | 0.00 | -2.01 | 14.53 |
| 2025-09-09 | ENTA | 0.00 | -2.01 | 14.53 |
| 2025-09-10 | ENTA | 0.00 | -2.01 | 14.53 |
| 2025-09-11 | ENTA | 0.00 | -2.01 | 14.27 |
| 2025-09-12 | ENTA | 0.00 | -2.01 | 14.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.85
Avg. EPS Est. Current Quarter
-1.01
Avg. EPS Est. Next Quarter
-1.02
Insider Transactions
Institutional Transactions
-2.01
Beta
0.82
Average Sales Estimate Current Quarter
15
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
20
Growth Score
25
Sentiment Score
4
Actual DrawDown %
91.9
Max Drawdown 5-Year %
-95.6
Target Price
18.57
P/E
Forward P/E
PEG
P/S
2.73
P/B
2.23
P/Free Cash Flow
EPS
-4.32
Average EPS Est. Cur. Y
-3.72
EPS Next Y. (Est.)
-3.21
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-141.98
Relative Volume
1.35
Return on Equity vs Sector %
-140.9
Return on Equity vs Industry %
-127.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.5
EBIT Estimation
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 131
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading